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Commentary
Regulatory agencies in the United States 
and the European Union (EU) have justi-
fied the decision to declare the estrogenic 
chemical bisphenol A (BPA) safe at current 
levels of human exposure based on a few 
studies conducted using Good Laboratory 
Practices (GLP). In contrast, these agencies 
have rejected for consideration in their risk 
assessment of BPA hundreds of laboratory 
animal and mechanistic cell culture studies 
conducted by academic and government sci-
entists reporting harm at very low doses of 
BPA. These studies were rejected primarily 
because they were not conducted using GLP. 
We suggest that decisions based on this logic 
are misguided and will result in continued 
risk to public health from exposure to BPA, 
as well as other manmade chemicals.
GLP is a federal rule for conducting 
research on the health effects or safety testing 
of drugs or chemicals submitted by private 
research companies for regulatory purposes. 
The GLP outlines basic guidelines for conduct-
ing scientific research, including the care and 
feeding of laboratory animals, standards for 
facility maintenance, calibration and care of 
equipment, personnel requirements, inspec-
tions, study protocols, and collection and 
storage of raw data (Goldman 1988). These 
regulations were developed in response to wide-
spread misconduct by private research compa-
nies; this misconduct was possible because their 
data usually do not go through the rigorous, 
multi  stage scientific review that is normal for 
academic data funded by federal agencies and 
published in the peer-reviewed literature. The 
lack of these safeguards from academic science 
had enabled fraud. The U.S. Food and Drug 
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Ba c k g r o u n d: In their safety evaluations of bisphenol A (BPA), the U.S. Food and Drug 
Administration (FDA) and a counterpart in Europe, the European Food Safety Authority (EFSA), 
have given special prominence to two industry-funded studies that adhered to standards defined by 
Good Laboratory Practices (GLP). These same agencies have given much less weight in risk assess-
ments to a large number of independently replicated non-GLP studies conducted with government 
funding by the leading experts in various fields of science from around the world.
oBjectives: We reviewed differences between industry-funded GLP studies of BPA conducted by 
commercial laboratories for regulatory purposes and non-GLP studies conducted in academic and 
government laboratories to identify hazards and molecular mechanisms mediating adverse effects. 
We examined the methods and results in the GLP studies that were pivotal in the draft decision of 
the U.S. FDA declaring BPA safe in relation to findings from studies that were competitive for U.S. 
National Institutes of Health (NIH) funding, peer-reviewed for publication in leading journals, 
subject to independent replication, but rejected by the U.S. FDA for regulatory purposes. 
discussion: Although the U.S. FDA and EFSA have deemed two industry-funded GLP studies of 
BPA to be superior to hundreds of studies funded by the U.S. NIH and NIH counterparts in other 
countries, the GLP studies on which the agencies based their decisions have serious conceptual and 
methodologic flaws. In addition, the U.S. FDA and EFSA have mistakenly assumed that GLP yields 
valid and reliable scientific findings (i.e., “good science”). Their rationale for favoring GLP studies 
over hundreds of publically funded studies ignores the central factor in determining the reliability and 
validity of scientific findings, namely, independent replication, and use of the most appropriate and 
sensitive state-of-the-art assays, neither of which is an expectation of industry-funded GLP research.
co n c l u s i o n s: Public health decisions should be based on studies using appropriate protocols with 
appropriate controls and the most sensitive assays, not GLP. Relevant NIH-funded research using 
state-of-the-art techniques should play a prominent role in safety evaluations of chemicals.
key w o r d s : bisphenol A, endocrine disruptors, FDA, Food and Drug Administration, GLP, good 
laboratory practices, low-dose, nonmonotonic, positive control. Environ Health Perspect 117:309–315 
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Administration (U.S. FDA) first issued rules 
for GLP in 1978 after a 2-year federal inves-
tigation into sloppy laboratory practices of a 
number of private research companies (Lublin 
1978; Markowitz and Rosner 2002). What 
began as serious concerns about poor quality 
research expanded into a criminal investiga-
tion of Industrial Bio-Test (IBT), one of the 
largest private laboratories at the time and a 
subsidiary of Nalco Chemical Company. In 
response to the federal investigation, the U.S. 
Environmental Protection Agency (EPA) 
demanded that 235 chemical companies re-
examine the > 4,000 tests conducted by the 
laboratory. In 1983, three men from IBT were 
found guilty of deliberating doctoring data 
and were sentenced to prison (Lublin 1978; 
Markowitz and Rosner 2002). The fraudulent 
practices of IBT brought into question 15% of 
the pesticides approved for use in the United 
States. That same year, the U.S. EPA issued 
similar GLP rules for regulatory testing.
Both the U.S. FDA (2008a) and European 
Food Safety Authority (ESFA 2006) have 
recently published documents demonstrating 
that their decision to continue to declare BPA 
safe at current exposure levels was based pri-
marily on the results of a few industry-funded 
studies that followed GLP guidelines. These 
decisions stand in stark contrast to the deci-
sions concerning the potential risks to human 
health reached by a panel of 38 experts at a 
U.S. National Institutes of Health (NIH)-
sponsored conference, who published The 
Chapel Hill Consensus Statement (vom Saal 
et al. 2007), as well as five review articles (Crain 
et al. 2007; Keri et al. 2007; Richter et al. 
2007a; Vandenberg et al. 2007a; Wetherill 
et al. 2007). These peer-reviewed articles cov-
ered approximately 700 articles concerning 
BPA and represented a comprehensive review 
of the literature as of the end of 2006. In 
addition, the U.S. FDA draft decision contra-
dicted the conclusions reached by the National 
Toxicology Program (NTP), which had spent 
2 years investigating this question (NTP 2008). 
An important role of the NTP is to advise the 
U.S. FDA about the science relating to toxic 
chemicals in food, but in an unusual move, 
the U.S. FDA chose to release its draft report 
before the release of the final report on BPA 
by the NTP and without indicating who at the 
U.S. FDA was involved in preparing the draft 
report (U.S. FDA 2008b). At a hearing on 
16 September 2008 regarding the draft report 
on BPA, the U.S. FDA announced that their 
goal was to have a subcommittee of the U.S. 
FDA Science Board complete a review of the 
draft decision by the end of October 2008. 
This would presumably also involve review by 
the sub  committee members of the approxi-
mately 1,000 articles relating to BPA.
We believe that the methods employed in 
chemical industry–sponsored GLP studies are 
incapable of detecting low-dose endocrine- 
disrupting effects of BPA and other hormon-
ally active chemicals. Detecting endocrine-
disrupting effects at low doses of chemicals 
such as BPA requires sophisticated and mod-
ern assays and analyses that have been devel-
oped in advanced, usually federally funded 
laboratories over the past decade. This is espe-
cially apparent when one examines what is 
now known about functional effects of BPA 
on a wide range of end points (Richter et al. 
2007a; Welshons et al. 2006; Wetherill et al. 
2007). These end points include those medi-
ated by recently discovered estrogen response 
pathways initiated in human and animal cell 
membranes (nonclassical or alternative estro-
gen response mechanisms), which multiple 
laboratories have shown to be equally sensitive 
to BPA and estradiol in terms of activating 
effects in human and animal cells at low pico-
molar through low nanomolar concentrations 
(Alonso-Magdalena et al. 2008; Wetherill 
et al. 2007; Wozniak et al. 2005; Zsarnovszky 
et al. 2005). 
The effects of BPA documented in these 
studies include a diverse array for which there 
are no data from GLP studies because the 
end points have not been examined: altered 
metabolism related to metabolic syndrome 
(Alonso-Magdalena et al. 2005, 2006, 2008; 
Ropero et al. 2008); altered adiponectin secre-
tion (Hugo et al. 2008), which is a condition 
predicting heart disease and type 2 diabetes 
(Lang et al. 2008); altered epigenetic pro-
gramming leading to precancerous lesions 
of the prostate (Ho et al. 2006); differential 
growth patterns in the developing prostate 
(Timms et al. 2005); abnormal growth, 
gene expression, and precancerous lesions 
of the mammary glands (Soto et al. 2008); 
and adverse effects on the female reproduc-
tive system, including uterine fibroids, para-
ovarian cysts, and chromosomal abnormalities 
in oocytes (Newbold et al. 2007; Susiarjo 
et al. 2007). There is also a large literature 
on neuro  anatomic, neurochemical, and 
behavioral abnormalities caused by low doses 
of BPA (Leranth et al. 2008; Richter et al. 
2007a), which also are not capable of being 
detected by current GLP studies conducted 
for regulatory purposes because of their out-
of-date assays.
The approaches used by academic and 
government scientists to study the potential 
health hazards of BPA contrast sharply with 
those still used by the chemical industry that 
are relied on by regulatory agencies in the 
United States and Europe, including the two 
studies identified by both the U.S. FDA and 
European Food Safety Authority (EFSA) as 
central to the decision to declare BPA safe 
at current human exposure levels (Tyl et al. 
2002, 2008a). By using outdated and insensi-
tive assays that were supposed to have been 
replaced by a new battery of screens and tests 
by 2000 [as mandated by the U.S. Congress 
in 1996 in the Food Quality Protection 
Act (1996), but which has, as yet, still not 
occurred], these studies conducted using GLP 
fail to find any adverse effects. 
Reliability and Validity
Reliability and validity are separate issues, 
although in the experimental research described 
here, validity and reliability basically refer to 
research that is credible. Golafshani (2003) 
noted that “reliability” refers to the extent to 
which results are consistent over time and are 
an accurate representation of the total popu-
lation under study. Of central importance is 
that the results of a study must be reproduced 
under a similar methodology to be considered 
to be reliable. “Validity” refers to whether 
the research measures what it was intended 
to meas  ure, and valid findings are considered 
to be true. In other words, reliability is deter-
mined by whether the results are replicable, 
whereas validity is assessed by whether the 
methods used result in finding the truth as a 
result of the investigator actually measuring 
what the study intended to measure.
Use of GLP in Regulatory 
Decision Making
Despite strong evidence of aberrations caused 
by low doses of BPA in animals exposed 
during fetal and neonatal life in studies con-
ducted by the world’s leading academic and 
government experts in the fields of endocrine 
disruption, endocrinology, neuro  biology, 
reproductive biology, genetics, and metabo-
lism, a relatively small number of studies 
reporting no adverse effects at low doses of 
BPA have continued to be promoted by the 
chemical industry and used by regulatory 
agencies (e.g., Ashby et al. 1999; Cagen et al. 
1999; Tyl et al. 2002, 2008a). According to 
the U.S. FDA, these are accepted because they 
used GLP (U.S. EPA 2008), with the implica-
tion that studies not employing GLP are not 
reliable or valid (U.S. FDA 2008a). 
GLP does not guarantee reliability or 
validity of scientific results. Unfortunately, 
although GLP creates the semblance of reli-
able and valid science, it actually offers no 
such guarantee. GLP specifies nothing about 
the quality of the research design, the skills of 
the technicians, the sensitivity of the assays, 
or whether the methods employed are current 
or out-of-date. (All of the above are central 
issues in the review of a grant proposal by 
an NIH panel.) GLP simply indicates that the 
laboratory technicians/scientists performing 
experiments follow highly detailed U.S. EPA 
requirements [or in the EU, Organization for 
Economic Co-operation and Development 
(OECD) requirements] for record keep-
ing, including details of the conduct of the GLP is not a guarantee of reliable science
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experiment and archiving rele  vant biological 
and chemical materials (U.S. EPA 2008). 
These record-keeping procedures in GLP 
were instituted because of widespread mis-
conduct being committed by commercial 
testing laboratories (described above). These 
fraudulent results were possible because con-
tract laboratory studies used in the regula-
tory process are rarely subject to the checks 
and balances that peer-reviewed, replicated 
scientific findings undergo. Without that 
acid test of reliability (replication by other 
independent scientists), other procedures 
were needed. Hence GLP was implemented, 
despite its severe limitations. 
NIH-funded research subject to more strin-
gent reviews than GLP. Although few NIH-
funded investigators adhere to GLP-mandated 
record keeping, the procedures of GLP are 
actually surpassed by the procedures required 
for NIH-funded science published in peer-
reviewed journals. NIH-funded studies pass 
through three phases of peer review that are 
far more challenging than GLP requirements. 
First, the principal scientists must have dem-
onstrated competence to conduct the research, 
and experimental methods, assays, and labora-
tory environment must involve use of state-of-
the-art techniques to be competitive for NIH 
funding. Second, results are published in peer-
reviewed journals, with detailed evaluations 
by independent experts examining all aspects 
of the study. And third, the findings are chal-
lenged by independent efforts to replicate; for 
example, the initial findings concerning the 
stimulating effects of estrogenic chemicals on 
the mouse prostate (Nagel et al. 1997; vom 
Saal et al. 1997) were independently replicated 
and extended by Gupta (2000), which led to 
an editorial identifying “initial results con-
firmed” (Sheehan 2000). 
Typically, within a laboratory, interest-
ing findings are also followed by subsequent 
publications extending the prior findings; 
examples include the findings of BPA effects 
on β cells in the mouse pancreas (Alonso-
Magdalena et al. 2005, 2006, 2008) and the 
effects of estrogenic chemicals and drugs on 
the developing mouse prostate that followed 
earlier findings (described above) from this 
same group (Timms et al. 2005; Richter et al. 
2007b). In particular, independent replica-
tion by competent, respected scientists is the 
main criterion of acceptance of the findings as 
having been demonstrated to be reliable and 
having been validated by virtue of coming to 
the same conclusion using a variety of sophis-
ticated techniques in multiple publications. 
An important criticism of the approach 
taken by the U.S. FDA in its assessment of 
the now approximately 1,000 articles on BPA 
is that it appears to have made no attempt 
to connect the dots between replicated stud-
ies; instead, the U.S. FDA appears to have 
assessed each study without regard to whether 
it had been confirmed by other studies. 
Thus, collectively, many phases used to 
verify the reliability and validity of NIH-
funded published research have been com-
pletely ignored by the U.S. FDA, whereas 
industry-funded GLP research is rarely, if 
ever, subject to these central requirements and 
yet is accepted by regulatory agencies as reli-
able and valid. 
The U.S. FDA’s misguided gold standard. 
In this light, the U.S. FDA’s reliance upon 
GLP as the gold standard is scientifically mis-
guided. Furthermore, U.S. FDA administra-
tors are ignoring published critiques of the 
GLP studies it considers reliable and valid, 
such as the study by Tyl et al. (2002) and two 
coordinated studies conducted at the same 
time by Ashby et al. (1999) and Cagen et al. 
(1999). Each was an industry-funded study 
conducted using GLP. Each was harshly 
criticized in peer-reviewed publications by 
academic scientists and government pan-
els [Center for the Evaluation of Risks to 
Human Reproduction (CERHR) 2007; NTP 
2001; vom Saal and Hughes 2005; vom Saal 
and Welshons 2006]. Yet, the U.S. FDA 
and EFSA panels still assert that these stud-
ies represent the gold standard in toxicologic 
research. 
Specifically, the studies of Cagen et al. 
(1999) and Ashby et al. (1999) were recently 
rejected by the NTP CERHR panel on BPA 
as unusable for consideration in its evaluation 
of the health hazards posed by BPA (CERHR 
2007). Both the Ashby et al. (1999) and Cagen 
et al. (1999) studies reported finding no effect 
of their positive control [the estrogenic drug 
diethylstilbestrol (DES)] on any outcome, 
although these failures were not acknowledged 
by the authors in either article. In experimen-
tal science, the failure of a positive control 
to show an effect indicates the experiment 
failed, which is the conclusion reached by the 
CERHR panel (CERHR 2007). 
The Tyl et al. 2002 study, which the U.S. 
FDA still accepts as a major study for determi-
nation of the safety of BPA (U.S. FDA 2008a, 
2008b), was criticized by an NTP panel that 
met in 2000 to examine the low-dose issue 
(NTP 2001), as well as in subsequent publica-
tions (vom Saal and Hughes 2005; vom Saal 
and Welshons 2006), for using an insensitive 
rat (the CD-SD rat) that requires extremely 
high doses (≥ 50 µg/kg/day) of the potent 
estrogenic drug ethinylestradiol to show 
effects such as those examined in the study by 
Tyl et al. (2002). This dose of ethinylestradiol 
is > 100 times higher than the approximately 
0.3 µg/kg/day used by women in oral con-
traceptives. The fact that Tyl et al. (2002) 
adhered to GLP did not protect them from 
using insensitive animals. This led the NTP 
(2001) to state: 
Because of clear species and strain differences 
in sensitivity, animal model selection should be 
based on responsiveness to endocrine-active agents 
of concern (i.e., responsive to positive controls), 
not on convenience and familiarity.
Thus, when reviewed by other scientists, 
three prior major GLP studies of BPA have 
been found to be so flawed as to be useless 
for guiding regulatory agencies in decision 
making. A new GLP study has now been pub-
lished by Tyl et al. (2008a). Close examina-
tion of this study also reveals fatal flaws which 
render it useless for regulatory purposes, even 
though it conforms to GLP.
Examples of Flaws Ignored by 
the U.S. FDA and EFSA in a 
Recent GLP Study of BPA 
In summary, the flaws in Tyl et al. (2008a) 
are as follows:
•	The	high	dose	required	for	the	positive	con-
trol (estradiol) to cause an effect means the 
system used by Tyl et al. (2008a), at least 
in her laboratory, is relatively insensitive to 
exogenous estrogens and thus inappropri-
ate for studying low-dose effects of estro-
genic compounds such as BPA. The lack 
of response to low doses of estradiol or 
BPA in the Tyl laboratory is puzzling, in 
that the strain of mice used in these experi-
ments (the CD-1 mouse) has been reported 
in > 20 other peer-reviewed publications to 
show adverse effects in response to very low 
doses of BPA (vom Saal 2008), as well as 
many other studies showing low-dose effects 
in response to the natural hormone estra-
diol, the estrogenic drugs ethinylestradiol 
and DES, and to other estrogenic chemicals.
•	Tyl	et	al.	(2008a)	used	insensitive,	out-of-
date protocols and assays that are incapa-
ble of finding many of the adverse effects 
reported by more sophisticated studies 
conducted by independent NIH-funded 
scientists as well as scientists funded by gov-
ernment agencies in other countries.
•	In	the	specific	case	of	testing	for	changes	in	
prostate weight, Tyl et al. (2008a) reported 
an abnormally high prostate weight for con-
trol animals that exceeds by > 70% the pros-
tate weights reported by other studies for 
animals of the same strain and similar age 
(e.g., Gupta 2000; Ruhlen et al. 2008). This 
suggests that the dissection procedures for 
the prostate in the Tyl laboratory included 
other non  prostatic tissues in the weight 
measurements, rendering them unusable for 
studying weight changes in the prostate in 
response to BPA or estradiol; neither chemi-
cal showed any effect on the selected end 
points, which directly contradicts other find-
ings concerning opposite effects of low and 
high doses of estrogen on the prostate (Putz 
et al. 2001; Timms et al. 2005; vom Saal 
et al. 1997).Myers et al.
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Aberrant insensitivity of CD-1 mouse to 
estrogens. Tyl et al. (2008a) used estradiol as 
a positive control. It was fed to female mice 
before and during pregnancy and lactation at 
80–220 µg/kg/day; after weaning, estradiol was 
fed to offspring at doses of 80–100 µg/kg/day. 
Estradiol was used as a positive control because 
BPA is a man-made endocrine-disrupting 
estrogenic chemical. 
Many published findings reporting effects 
of very low doses of positive control estro-
gens and BPA in CD-1 mice demonstrate 
that the CD-1 mouse was somehow rendered 
insensitive in the test system used by Tyl et al. 
(2008a). The fact that a dose of 100–200 µg/
kg/day estradiol was necessary to show an 
effect of the positive control predicts that Tyl 
et al. (2008a) should not detect effects of BPA 
< 10–100 mg/kg/day, far above the low-dose 
range relevant to human exposures that was 
supposedly of interest. 
For nuclear estrogen receptor–mediated 
effects via regulation of gene activity (nuclear 
estrogen receptors are transcription fac-
tors whose activity is regulated by binding to 
estrogen), prior studies have typically shown 
a 1,000-fold lower activity for BPA relative to 
estradiol or potent estrogenic drugs, includ-
ing DES and ethinylestradiol. For example, 
Richter et al. (2007b) reported an increase in 
androgen receptor gene activity to estradiol 
at 1 pM (0.28 pg/mL) in fetal CD-1 mouse 
prostatic mesenchyme cells in primary culture, 
and the same response was found for BPA at 
1,000 pM (228 pg/mL); the in vitro response 
to estradiol was predicted by the response of 
the prostate to increasing free serum estradiol 
from 0.2 to 0.3 pg/mL in male mouse fetuses 
via estradiol administration to the mother 
(vom Saal et al. 1997). Other research showed 
that a significant effect on development of 
the male reproductive system in CF-1 mice 
occurred at a maternal dose of 0.002 µg/kg/day 
ethinylestradiol (Thayer et al. 2001), similar 
to effects observed with 2–20 µg/kg/day BPA 
(vom Saal et al. 1998). The research of Honma 
et al. (2002) showed accelerated puberty in 
CD-1 (ICR) mice at a DES dose of 0.02 µg/
kg/day (the positive control), and the same 
response to BPA occurred at 20 µg/kg/day, 
again revealing a 1,000-fold difference between 
the positive control estrogen and BPA. 
There are many other examples of findings 
where a higher dose of BPA was required to 
cause the same effect as the positive control 
estrogen (estradiol, ethinylestradiol, or DES) in 
studies where the effects were mediated by the 
classical nuclear estrogen receptors, in contrast 
to the more recently discovered rapid signaling 
estrogen response system where BPA and these 
positive control estrogens have equal potency, 
as described above. In summary, CD-1 mice 
have been used by a large number of academic 
and government investigators and have been 
reported in peer-reviewed publications to be 
sensitive to positive control estrogens within 
the range of human sensitivity based on in vivo 
and in vitro studies via the classical estrogen 
receptor α–mediated response mechanism. 
The CD-1 mouse is the animal model that has 
been used by the U.S. National Institute of 
Environmental Health Sciences (NIEHS) for 
decades, because it is considered the best ani-
mal model for predicting the effects of devel-
opmental exposure to estrogen in humans 
(Newbold 1995; Newbold et al. 2007). 
The failure of traditional toxicologic stud-
ies conducted by Tyl et al. (2008a, 2008b) 
to detect the wide range of adverse effects of 
even relatively high doses of BPA or of low 
doses of estradiol that have been reported in 
numerous studies by academic and govern-
ment scientists provides evidence that the GLP 
protocols established long ago by regulatory 
agencies to determine the toxicity of chemicals 
are inappropriate for detecting the endocrine-
disrupting activities of chemicals such as BPA. 
Indeed, this was the premise of the congres-
sional mandate in the Food Quality Protection 
Act (1996) for the U.S. EPA to establish a new 
set of assays for endocrine-disrupting chemicals, 
although this process has been systemati  cally 
delayed and is > 8 years behind the congres-
sionally mandated date of 2000 to have these 
new assays validated. 
Citing Tyl et al. (2008a), the EFSA report 
on BPA (EFSA 2006) stated that “the posi-
tive control substance, 17β-estradiol, resulted 
in reproductive and developmental toxicity.” 
This report failed to acknowledge that only a 
very high dose of the positive control was suf-
ficient to elicit effects and that this meant that 
the experiments conducted in the Tyl labora-
tory were for some reason very insensitive to 
any estrogen and thus inappropriate for use in 
a study to examine low-dose estrogenic effects 
of BPA. 
Based on the preliminary report released 
by the U.S. FDA regarding BPA (U.S. FDA 
2008a), it appears that the U.S. FDA has 
followed the lead of the EFSA in its lack of 
understanding of the importance of the dose 
of the positive control estrogen required to 
cause adverse effects. The consequence is that 
the U.S. FDA has relied primarily on the study 
of Tyl et al. (2008a, 2008b), with the result 
that the U.S. FDA has assured Americans that 
BPA is safe at current human exposure levels.
Several factors might account for the insen-
sitivity of the CD-1 mouse in the Tyl et al. 
studies (2008a, 2008b) conducted at Research 
Triangle Institute (RTI), a testing facility that 
conducted these (as well as previous) studies 
funded by the American Chemistry Council. 
One possibility is that the diet used in these 
studies may have interfered with the results. 
The feed used by Tyl et al. (2008a) in this 
experiment (Purina 5002) has been shown by 
others to interfere with responses to exogenous 
estrogenic chemi  cals, blocking adverse effects 
documented on other diets. For example, a 
number of years ago, Thigpen et al. (2003) at 
the NIEHS recommended against the use of 
Purina 5002 in studies of endocrine-  disrupting 
chemicals. Tyl et al. (2008a) measured some 
specific phyto  estrogens in Purina 5002 feed 
by chemical analysis; however, in a report 
on NIH-sponsored meetings on this subject, 
Heindel and vom Saal (2008) pointed out that 
this is an insufficient control for total dietary 
estrogenic contaminants that can disrupt stud-
ies involving the effects of estrogenic chemicals. 
A second possibility is that there are 
strain differences in sensitivity developed in 
the CD-1 mouse sold by the various Charles 
River Laboratories located in different regions. 
We consider this unlikely, because most labo-
ratories regularly replace their CD-1 mouse 
breeder stock from Charles River Laboratories, 
and practices there make it unlikely that the 
sensitivity of this outbred stock to estrogens 
has changed dramatically over a very short 
period of time. Also, because RTI, where the 
Tyl studies were conducted, is very near the 
laboratories of the NIEHS, it is likely that the 
CD-1 mice used by these two programs were 
purchased from the same breeding facility.
Use of insensitive, out-of-date protocols and 
assays. Another serious concern about the two 
recent studies by Tyl et al. (2008a, 2008b) is 
the experimental approach used, thus raising 
questions about the validity of the studies. 
The study design used by Tyl et al. (2008a, 
2008b) has been super  seded by advances in 
both experimental design and analytical tools 
developed by NIH-funded scientists (and their 
counterparts in Europe and Asia) since the 
mid-1990s. The methods used by Tyl et al., 
primarily wet weight changes of tissues, gross 
histologic changes, and developmental land-
marks such as vaginal opening, were estab-
lished procedures by the 1950s. Thus, a major 
limitation of the Tyl studies is the failure to 
measure more meaningful and sensitive end 
points in order to detect the effects of low-dose 
BPA exposure, which are often not macro-
scopic in nature. Indeed, in 2001, the director 
of the reproductive division of the National 
Health and Environmental Effects Research 
Laboratory at the U.S. EPA stated that the 
inconclusive results concerning effects of BPA 
on reproductive toxicology can only be solved 
by understanding the mechanisms (Triendl 
2001). With current GLP standards it is not 
possible to study mechanisms because they 
still rely on out-of-date assays.
As one example of a comparison between 
the approach by Tyl et al. (2008a) and inde-
pendent government-funded academic scien-
tists, extensive research has been conducted 
by Soto et al. (2008) and by other indepen-
dent academic and government scientists GLP is not a guarantee of reliable science
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describing effects of exposure of female mice 
and rats to very low doses of BPA during peri-
natal development on the mammary glands 
(Jenkins et al. 2009). Although Tyl et al. 
(2008a) reported no low-dose effects of BPA 
on the mammary glands using conventional 
histologic analysis, there have been consistent 
findings of adverse effects of low doses of BPA 
from studies that used more sophisticated and 
sensitive analysis of whole mounted mam-
mary glands to facilitate detection of micro-
scopic lesions, coupled with immunos  taining 
for regulatory proteins as well as techniques 
for determination of aberrant gene expression 
associated with progression to cancer. These 
peer-reviewed studies have reported detect-
ing changes during embryonic development 
of mammary glands as well as abnormalities 
detected during adolescence through adult-
hood that are indicative of mammary gland 
cancer as well as other developmental abnor-
malities (Colerangle and Roy 1997; Durando 
et al. 2007; Jenkins et al. 2009; LaPensee et al. 
2008; Markey et al. 2001, 2005; Moral et al. 
2008; Munoz-de-Toro et al. 2005; Murray 
et al. 2007; Nikaido et al. 2004; Vandenberg 
et al. 2006, 2007b; Wadia et al. 2007). 
Similar to the findings for the mammary 
gland, Ogura et al. (2007) reported that if 
tissues were analyzed by conventional his-
tologic methods (staining with hematoxalin 
and eosin), prenatal exposure to low doses of 
BPA or DES showed no effects on prostate 
development, whereas if the sections were 
analyzed using antibodies that identified basal 
cells and basal cell squamous metaplasia, then 
significant effects were revealed. Squamous 
metaplasia of basal cells indicates abnormal 
proliferation and function of the prostate stem 
cell population that is thought to transform 
into neoplastic cells; Ho et al. (2006) reported 
that neonatal exposure to very low doses of 
BPA caused 100% of male rats to develop 
high-grade prostatic intra  epithelial neoplastic 
lesions later in life. All of these studies were 
rejected by the U.S. FDA as not adequate for 
making regulatory decisions about the safety 
of BPA. Instead, the U.S. FDA relied upon 
Tyl et al. (2008a), even though the study used 
techniques that Ogura et al. (2007) showed 
lacked the sensitivity of 21st century experi-
mental approaches. 
Although findings regarding changes in 
brain structure, brain chemistry, and behav-
ior represent the largest portion of the litera-
ture on low-dose BPA, Tyl et al. (2008a) did 
not examine any neuro  behavioral end points. 
The NTP (2008) and the NIEHS confer-
ence consensus reports (vom Saal et al. 2007) 
both indicated concern about neuro  behavioral 
effects of low doses of BPA. Thus, the absence 
of studies that included neuro  behavioral 
end points is a glaring omission of Tyl et al. 
(2008a, 2008b). 
Flawed prostate dissection. Data presented 
by Tyl et al. (2008a) raise questions about the 
adequacy of techniques used in their BPA stud-
ies. Specifically, Tyl et al. (2008a) reported that 
the prostate in 3.5-month-old control male 
CD-1 mice weighed > 70 mg [see Table 3 
in Tyl et al. (2008a) for data on F1 retained 
males]. This average control weight contrasts 
sharply with those reported from other labo-
ratories. Specifically, the weight of the prostate 
in 2- to 3-month-old CD-1 mice using the dis-
section technique based on both Ruhlen et al. 
(2008) and Gupta (2000) and at the NIEHS 
(Newbold RR, personal communication) is 
about 40 mg. Several studies have reported that 
prenatal exposure to very low doses of BPA and 
positive control estrogens increased prostate 
size, prostatic androgen receptors, and pros-
tate androgen receptor gene activity (Gupta 
2000; Richter et al. 2007b; Thayer et al. 2001; 
Timms et al. 2005; vom Saal et al. 1997), but 
the enlarged prostate of experimental animals 
exposed to BPA in these laboratories weighed 
less than the prostates in the control animals of 
Tyl et al. (2008a). This raises serious questions 
about the procedures and/or animals used by 
Tyl et al. The weight of prostate reported by 
Tyl et al. (2008a) suggests that the technique 
used for dissecting the prostate resulted in non-
prostatic tissue being weighed along with pros-
tate. The seminal vesicle, coagulating gland, 
and dorso  lateral prostate all merge together 
where the ejaculatory ducts enter the urethra, 
and there are also fat deposits on the prostate. 
This poses a challenge for those without proper 
training in distinguishing these different tissues 
during dissection in mice. 
Alternatively, as male rodents age, they 
are prone to develop prostatitis. Although 
this inflammatory disease leads to an increase 
in prostate size and could thus account for 
the very large prostate weights reported by 
Tyl et al. (2008a), anyone familiar with the 
appearance of prostatitis would detect this 
abnormality upon histologic examination, 
which Tyl et al (2008a) supposedly con-
ducted. Also, prostatitis is rare in young-adult 
mice or rats (Cowin et al. 2008), and the size 
of the prostates in the Tyl et al. (2008a) study 
were similar to those for middle-aged and old 
male mice.
The findings regarding effects of BPA on 
the prostate presented by Tyl et al. (2008a) 
are thus suspect and cannot be used as evi-
dence that other earlier studies (Gupta 2000; 
Timms et al. 2005; vom Saal et al. 1997) are 
not replicable. Given these problems in pros-
tate weight measurements, it is not surprising 
that even very high doses of BPA or estradiol 
reported by Tyl et al. (2008a) had no effect on 
the prostate, in sharp contrast to other studies 
that showed stimulation of the prostate at low 
doses of estrogen and inhibition at high doses 
(Putz et al. 2001; Timms et al. 2005). 
In addition to the problem associated 
with the high prostate weight reported by Tyl 
et al. (2008a), in a separate measurement the 
authors combined the anterior prostate (coagu-
lating gland) and seminal vesicle, presenting 
these two organs as one combined outcome 
meas  ure. This is wrong and misleading. The 
coagulating glands emerge as the anterior ducts 
of the prostate from the dorso  cranial region 
of the uro  genital sinus, whereas the seminal 
vesicles bud from the proximal region of the 
Wolffian ducts. Elevated estrogen is associ-
ated with an increase in prostate size associated 
with an increase in prostate androgen recep-
tors, whereas a decrease in seminal vesicle size 
is associated with a reduction in 5α-reductase, 
an enzyme that converts testosterone to the 
more potent androgen 5α-dihydrotestosterone 
(Nonneman et al. 1992). Low doses of BPA 
have been shown to decrease the size of organs 
that differentiate from the embryonic Wolffian 
ducts (epididymides and seminal vesicles) 
while increasing the size of regions of the pros-
tate that develop from the uro  genital sinus 
(vom Saal et al. 1998). Combining these dif-
ferent organs (it is technically not difficult to 
separate them) was thus inappropriate because 
they develop from different embryonic tis-
sues that show markedly different responses to 
estrogenic chemicals during development. In 
fact, Ogura et al. (2007) reported that the ante-
rior prostate (coagulating glands) showed the 
greatest expression of ER-α, and also showed 
the most pronounced indication of basal cell 
squamous metaplasia in response to develop-
mental exposure to low doses of DES and BPA 
relative to other regions of the prostate.
Conclusions
Because the control data of Tyl et al. (2008a) 
were not consistent with the prior published 
literature for prostate weight of young-adult 
CD-1 male mice and because their methods 
were inappropriate for revealing an extensive 
body of adverse effects detected using more 
sophisticated approaches, we deem the find-
ings by Tyl et al. to be invalid. Hundreds of 
studies show adverse effects of BPA in ani-
mals, with many conducted at concentrations 
equivalent to current human levels of BPA 
exposure; thus, it is unlikely that academic sci-
entists would bother to replicate the outdated 
approaches used by Tyl et al. (2008a, 2008b). 
This lack of replication is typical of GLP stud-
ies, which tend to involve unnecessarily large 
numbers of animals [Tyl et al. (2002) used 
> 8,000 rats], and reliability appears to be 
accepted because of the numbers of animals 
that were used. Although using excessive 
numbers of animals is accepted as good sci-
ence by the U.S. FDA, the use of arbitrarily 
large numbers of animals per group (> 20 ani-
mals per treatment group is common) actually 
violates guidelines in the NIH Guide for the Myers et al.
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Care and Use of Laboratory Animals (Institute 
of Laboratory Animal Research 1996) that 
govern research conducted by academic and 
government scientists. For research with ani-
mals to be approved by any university animal 
care and use committee, group sizes must be 
based on power analysis conducted using his-
toric data. Based on this criterion in the NIH 
Guide, all of the studies by Tyl et al. were 
significantly over powered and thus in direct 
violation of federal guidelines for conducting 
animal research, a fact about which U.S. FDA 
regulators seem unaware.
Each of the four main industry-funded 
GLP studies of BPA (Ashby et al. 1999; Cagen 
et al. 1999; Tyl et al. 2008a, 2008b) is flawed 
and not appropriate for use in setting health 
standards. Clearly, meeting GLP standards is 
not a guarantee of reliable or valid science. It is 
of great concern that the U.S. and EU regula-
tory communities are willing to accept these 
industry-funded, antiquated, and flawed stud-
ies as proof of the safety of BPA while rejecting 
as invalid for regulatory purposes the findings 
from a very large number of academic and gov-
ernment investigators using 21st-  century scien-
tific approaches. The basis for these decisions 
by U.S. and EU regu  la  tory agencies should 
be thoroughly investigated, particularly since 
the NTP (2008) concluded that BPA expo-
sure to human infants was in the range shown 
to cause harm in experimental animals and 
since both the Canadian Ministry of Health 
and the Ministry of the Environment recently 
concluded that BPA was a toxic chemical 
(Environment Canada 2008).
Problems inherent with reliance on GLP 
as the standard for choosing data are com-
pounded by the process used by federal agen-
cies to determine membership on science 
advisory panels. Leading experts qualified by 
specific experience on the chemical or end 
points under consideration are often specifi-
cally excluded from membership. For example, 
the U.S. FDA’s BPA review panel was identi-
fied as an expert panel, when in fact the panel 
was composed largely of scientists lacking any 
experience in research with BPA. This process, 
which appears to consider almost any scientist 
knowledgeable about a chemical to create bias, 
makes it vastly more difficult for the panel 
to integrate scientific data from the relevant 
literature, especially since, as with BPA, there 
are almost 1,000 relevant studies and the 
review panel is provided with very little time 
to become knowledgeable about the details. 
It means that the depth of knowledge pres-
ent on this and similarly constituted govern-
ment regulatory agency panels is unlikely to 
be sufficient to subject draft assessments to the 
scrutiny that peer review by experts normally 
entails. Combined with reliance on GLP data, 
this process has a high potential to yield flawed 
assessments that jeopardize public health. 
We are not suggesting that GLP should 
be abandoned as a requirement for industry-
funded studies. We object, however, to regu-
latory agencies implying that GLP indicates 
that industry-funded GLP research is some-
how superior to NIH-funded studies that are 
not conducted using GLP. This argument 
demonstrates a lack of understanding of the 
profound difference between the use of repli-
cation as a mechanism to assess reliability and 
the methods used to assess validity for peer-
reviewed published academic studies, whereas 
GLP was instituted with the expectation that 
this type of verification would not occur. 
Public health decisions should be based 
on studies using appropriate protocols and 
the most sensitive assays. They should not be 
based on criteria that include or exclude data 
depending on whether or not the studies use 
GLP. Simply meeting GLP requirements is 
insufficient to guarantee scientific reliability 
and validity.
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